共 97 条
[1]
Forouzanfar MH(2011)Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis Lancet 378 1461-1484
[2]
Foreman KJ(2012)Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 vii11-19
[3]
Delossantos AM(2002)Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 15-18
[4]
Cardoso F(2005)Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011-1027
[5]
Harbeck N(2001)High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 5407-5414
[6]
Fallowfield L(1997)Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 963-969
[7]
Folkman J(2013)First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients Ann Oncol 24 2773-2780
[8]
Hicklin DJ(2012)Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence J Oncol 12 369-376
[9]
Ellis LM(2011)Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol 30 1484-1491
[10]
Foekens JA(2012)Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer J Clin Oncol 31 2870-2878